NAD+ restoration via precursor and geroprotector combinations
PrimaryAVEA-linked material frames age-related NAD+ decline as a contributor to disrupted biological function across hallmarks of aging and to higher risk of metabolic, cardiovascular, and neurodegenerative disease. The proposed intervention is supplementation with NAD+ precursors such as NMN or NR, potentially combined with other geroprotective compounds, to restore more youthful NAD+ levels. The causal mechanism is that geroprotectors may improve the efficacy of NAD+ precursor supplementation by reducing NAD+ degradation through CD38 inhibition and by supporting downstream SIRT1-linked protective pathways. Testable predictions include increased NAD+ availability, improved activity of NAD+/SIRT1-associated stress-response biology, and reduced biomarkers or incidence of age-related disease risk compared with precursor-only or placebo supplementation.
Popperian evaluation
The starting premise is biologically credible: NAD+ declines with age, and the CD38/NAD+/SIRT1 axis gives the theory a real mechanistic spine. The weak point is the jump from restoring NAD+ availability to reducing human disease risk. That step is plausible, but the supplied evidence does not show that precursor plus geroprotector combinations actually produce durable clinical benefit in humans.
Supporting evidence: The 2023 Nutrients review links age-related NAD+ decline to disrupted hallmarks of aging and proposes NMN or NR supplementation to restore NAD+ levels.; The same review describes CD38 inhibition and SIRT1-linked downstream pathways as mechanisms through which geroprotectors could improve NAD+ precursor effects.
Counter evidence: The disease-risk claim remains an assumption in the reasoning graph, with medium confidence rather than direct clinical proof.; The collagen amino acid paper supports broad nutraceutical plausibility, but it does not directly test NAD+ precursors, CD38 inhibition, or SIRT1 biology.
The theory explains why a combination might outperform NMN or NR alone: less NAD+ degradation through CD38 and more activity in SIRT1-linked stress-response biology. But the observed evidence is thin. A review can organize a mechanism, and a collagen study can show that some nutraceuticals may affect aging-related readouts, but neither proves that this specific combination explains human healthspan outcomes better than diet, exercise, baseline health, placebo effects, regression to the mean, or unrelated supplement mechanisms.
Supporting evidence: The theory predicts higher NAD+ availability and stronger NAD+/SIRT1-associated stress-response activity with combination supplementation than with precursor-only or placebo groups.; The framework connects upstream NAD+ preservation with downstream protective signaling, which gives it more explanatory structure than a simple 'take more precursor' claim.
Counter evidence: No supplied human trial compares placebo, precursor-only, and precursor plus geroprotector arms on NAD+ availability, SIRT1-linked activity, and disease-risk biomarkers.; The collagen observational trial has a different intervention and cannot separate the NAD+ theory from broader nutraceutical or behavioral explanations.
This theory is highly testable. A clean trial could randomize people into placebo, NAD+ precursor-only, geroprotector-only, and combination groups, then measure NAD+ metabolites, CD38 activity, SIRT1-linked pathway markers, and prespecified disease-risk biomarkers. If the combination does not beat precursor-only on NAD+ availability or downstream stress-response biology, the central mechanism takes a direct hit.
Supporting evidence: The reasoning graph names concrete comparison groups: precursor-only, geroprotector-combination, and placebo.; The predicted readouts are measurable: NAD+ availability, NAD+/SIRT1-associated stress-response activity, and age-related disease-risk biomarkers.
Counter evidence: The disease-incidence prediction would need large, long trials because metabolic, cardiovascular, and neurodegenerative outcomes develop over years.; The theory does not specify exact compounds, doses, target NAD+ thresholds, tissue compartments, or time windows, which leaves room for moving the goalposts after a weak result.
Reasoning tree
Public endorsements
The record shows Matilde Mantovani as part of AVEA's team and as Scientific Research Manager at Avea Life, but the provided evidence does not contain any public statement from her about NAD+ restoration, NMN, NR, geroprotectors, CD38, or SIRT1. On this dossier, she is publicly associated with the company, not with this theory in her own words.
Evidence publication IDs: d8a7f336-9dc6-4664-93c2-4cd2a0257da1, 9215c961-d0ca-420e-b0ac-2e487534fea6
No public quote, record, or publication in the provided evidence ties Soheil Saeedi Saravi to this NAD+ precursor plus geroprotector theory. With no documented statement to inspect, the defensible label is silence.
Sophie Chabloz is publicly linked to AVEA content that includes an article titled "What is NR, and how does it work?" NR is a core NAD+ precursor in the theory, so this is evidence of public mention. The dossier does not provide a direct quote or article text showing that she endorses the full claim about NAD+ restoration through precursor and geroprotector combinations.
Evidence publication IDs: 5f0f373c-e789-4ed1-a87c-9808c8f28dec, c6e87cca-d8db-460a-81cf-db942607645d